Summary
Drug discovery and development is time consuming and a costly procedure. The challenges for the pharmaceutical industry range from the evaluation of potential new drug candidates, the determination of drug pharmacokinetics/pharmacodynamics, the measurement of receptor occupancy as a determinant of drug efficacy, and the pharmacological characterisation of mechanisms of action. Positron emission tomography (PET) is a powerful quantitative imaging technique for looking at biochemical pathways, molecular interactions, drug pharmacokinetics and pharmacodynamics. Recent advances in emission tomography, particularly the development of small animal PET scanners, image reconstruction and animal models of disease have led to the development of extremely sensitive and specific tools for imaging biochemical processes in vivo, therefore representing a new means of providing information for drug development and evaluation. Many human genes have a related mouse gene, allowing mice to be used as a platform for mimicking human disease, using knock-out and knock-in gene technology. Consequently PET imaging of rodents is emerging as a cost effective means of screening new pharmaceuticals and decreasing the time required for new drug development.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Campbell, B. (1995) Drug development and positron emission tomography in PET for drug development and evaluation (Comar, D., ed) pp. 1–24, Kluwer Academic Publishers, Dordrecht.
Phelps, M. (2000): Positron emission tomography provides molecular imaging of biological processes., Proc. Natl. Acad. Sci. USA. 97, 9226–9233.
Herschman, H. (2003): Molecular imaging: looking at problems, seeing solutions. Science. 302, 605–608.
Czernin, J., & Phelps, M. (2002): Positron emission tomography scanning: current and future applications., Ann. Rev. Med., 53, 89–112.
Buck, A., Schirrmeister, H., Hetzel, M., Von Der Heide, M., Halter, G., Mattfeldt, T., Liewald, F., Reske, S., & Neumaier, B. (2002): 3-Deoxy-3-[18F]fluorothymidine positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules., Cancer Res., 62, 3331–3334.
Vesselle, H., Grierson, J., Muzi, M., Pugsley, J., Schmidt, R., Rabinowitz, P., Peterson, L., Vallieres, E., & Wood, D. (2002): In vivo validation of 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT) uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lund tumours., Clin. Cancer Res., 8, 3315–23.
Halldin, C., Gulyas, B., & Farde, L. (2001): PET studies with carbon-11 radioligands in neuropsychopharmacological drug development., Curr. Pharm. Des., 7, 1907–1929.
Maziere, B., & Loc’h, C. (2001): Using bromine-76 and iodine-123 radiohalogenated tracers in the drug development process., Curr. Pharm. Des., 7, 1931–1943.
Brady, F., Luthra, S., Brown, G., Osam, S., Aboagye, E., Saleem, A. & Price, P. (2001): Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET., Curr. Pharm. Des., 7, 1863–1892.
Hume, S. P., Brown, D., Ashworth, S., Hirani, E., Luthra, S. & Lammertsma, A. (1997): In vivo saturation kinetics of two dopamine transporter probes measured using a small animal scanner., J. Neurosci. Methods. 76, 45–51.
Chatziioannou, A. F. (2002): Molecular imaging of small animals with dedicated PET tomographs, Eur J Nucl Med Mol Imaging. 29, 98–114.
Myers, R., & Hume, S. P. (2002): Small animal PET, European Neuropsychopharmacology. 12, 545–555.
Del Guerra, A., & Belcari, N. (2002): Advances in animal PET scanners, Q. J. Nucl. Med., 46, 35–47.
Cherry, S. (1994): Recent advances in instrumentation for positron emission tomography., Nucl. Instr. & Methods in Phys. Res A., 348, 577–582.
Chatziioannou, A. F., Cherry, S., Shao, Y., Silverman, R., Meadors, K., Farquhar, T., Pedarsani, M., & Phelps, M. (1999): Performance evaluation of microPET: A high resolution lutetium oxyorthosilicate PET scanner for animal imaging., J. Nucl. Med., 40, 1164–1175.
DeJesus, O., Murali, D., Flores, L., Converse, A., Dick, D., Oaks, T., Roberts, A., & Nickles, R. (2003): Synthesis of [F-18]ZD1839 as a PET imaging agent for epidermal growth factor receptors., J. Labelled Comp. Radiopharm., 46, S1.
Haubner, R., Wester, H., Weber, W., Mang, C., Ziegler, S., Goodman, S., Senekowitsch-Schmidtke, R., Kessler, H., & Schwaiger, M. (2001): Noninvasiveimaging of αvβ3 integrin expression using18F-labeled RGB-containing glycopeptide and positron emission tomography., Cancer Res., 61, 1781–1785.
Solomon, B., McArthur, G., Cuillinane, C., Zalcberg, J., & Hicks, R. (2003): Applications of positron emission tomography in the development of molecular targeted cancer therapeutics., Biodrugs. 17, 339–354.
Wiebe, L., & Knaus, E. (2001): Enzyme-targeted, nucleoside-based radiopharmaceuticals for scintigraphic monitoring of gene transfer and expression., Curr. Pharm. Des., 7, 1893–1906.
Phelps, M. (2000): PET: The merging of biology and imaging into molecular imaging., J. Nucl. Med., 41, 661–681.
Tjuvajev, J., Avril, N., Oku, T., Sasajima, T., Miyagawa, T., Joshi, R., Safer, M., Beattie, B., DiResta, G., Daghighian, F., Augensen, F., Koutcher, J., Zweit, J., Humm, J., Larson, S., Finn, R., & Blasberg, R. (1998): Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography, Cancer Res., 58, 4333–4341.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roselt, P., Meikle, S. & Kassiou, M. The role of positron emission tomography in the discovery and development of new drugs; As studied in laboratory animals. European Journal of Drug Metabolism and Pharmacokinetics 29, 1–6 (2004). https://doi.org/10.1007/BF03190567
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190567